Form D · Pharmaceuticals

CerSci Therapeutics Inc.

Dallas, TX · CIK 0001790478

Offering snapshot reported Mar 20, 2020 · SEC filing

Reported sold: $12M
Investors reported: 24
Minimum accepted: $0
First sale: Apr 4, 2019

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$8,000,000 → $11,999,995
Minimum accepted$600 → $0

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Mar 20, 2020	Amendment	$11,999,995	$3,999,995vs Oct 8, 2019	24	SEC filing
Oct 8, 2019	Initial	$8,000,000	No comparison	24	SEC filing

Offering details

Securities: Equity, Debt, Option to acquire, Security to be acquired
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-350547

Source: Form D, filed Mar 20, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Tyler Brous	Director
Pat Confalone	Director
Scott Dax	Director
Brent Duncan	Director
David Genecov	Director
John D. Harkey, Jr.	Director
David Hitt Ii	Director
Perry Molinoff	Director
Dennis Robbins	Director
Lucas Rodriguez	Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

17217 Waterview Parkway Suite 1.202
Dallas, TX, 75252